|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2009-2-19
|
|
pubmed:abstractText |
CDKN2A/p16INK4a is frequently altered in human cancers and it is the most important melanoma susceptibility gene identified to date. p16INK4a inhibits pRb phosphorylation and induces cell cycle arrest, which is considered its main tumour suppressor function. Nevertheless, additional activities may contribute to the tumour suppressor role of p16INK4a and could help explain its specific association with melanoma predisposition. To identify such functions we conducted a yeast-two-hybrid screen for novel p16INK4a binding partners.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-10357768,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-10385618,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-10773875,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-10778858,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-10898786,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-10943845,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-11085541,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-11163203,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-11420722,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-11595726,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-12149641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-12244326,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-12809602,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-14673169,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-14729964,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-15141164,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-15240517,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-15287030,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-15623583,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-16291983,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-16648630,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-16894598,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-16998464,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-17047042,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-17544228,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-17546055,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-17578512,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-17582821,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-17637742,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-17666433,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-17938176,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-18239461,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-18267069,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-18483251,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-18843795,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-3943110,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-7796391,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19149898-9823308
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1476-4598
|
|
pubmed:author |
pubmed-author:BeckerTherese MTM,
pubmed-author:DiefenbachEveE,
pubmed-author:DijkstraMenno KMK,
pubmed-author:FraustoMonikaM,
pubmed-author:HaferkampSebastianS,
pubmed-author:KeffordRichard FRF,
pubmed-author:MannGraham JGJ,
pubmed-author:ReismanDavid NDN,
pubmed-author:RizosHelenH,
pubmed-author:ScolyerRichard ARA,
pubmed-author:ScurrLyndee LLL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19149898-Blotting, Western,
pubmed-meshheading:19149898-Cell Aging,
pubmed-meshheading:19149898-Cell Cycle,
pubmed-meshheading:19149898-Cell Line, Tumor,
pubmed-meshheading:19149898-Cyclin-Dependent Kinase Inhibitor p16,
pubmed-meshheading:19149898-DNA Helicases,
pubmed-meshheading:19149898-Humans,
pubmed-meshheading:19149898-Immunohistochemistry,
pubmed-meshheading:19149898-Immunoprecipitation,
pubmed-meshheading:19149898-Melanoma,
pubmed-meshheading:19149898-Nuclear Proteins,
pubmed-meshheading:19149898-Protein Binding,
pubmed-meshheading:19149898-Signal Transduction,
pubmed-meshheading:19149898-Transcription Factors,
pubmed-meshheading:19149898-Two-Hybrid System Techniques
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a.
|
|
pubmed:affiliation |
Westmead Institute for Cancer Research, University of Sydney, Westmead Millennium Institute and Westmead Hospital, Australia. therese_becker@wmi.usyd.edu.au
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
